logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Resistance and Progression Mechanisms in Prostate Cancer

imatge Central Grup Recerca

Scientific Team

Researchers
Alvaro Aytes
Postdoctoral researchers
Katia Ruggero
Technicians
Alba Calvet
Support staff
Luis Palomero

Introduction

Prostate cancer is the most commonly diagnosed malignancy among men and the second leading cause of cancer-related mortality in developed countries. While a majority of patients face very favorable outcomes and are unlikely to succumb from the disease, a subset will progress to more aggressive forms that are highly metastatic. In these cases, treatment options are initially effective but therapeutic resistance eventually occurs leading to an associated mortality.

 

The lab is located in the Bellvitge Biomedical Research Institute  (IDIBELL ) in Barcelona, and is afiliated with the Catalan Institute of Oncology within the Program Against Cancer Therapeutic Resistance (ProCURE). We also recieve funding from the ISCIIIEuropean Association of Urology (EAU) and the Fundacion BBVA.



Research lines

  • Mechanisms in metastatic progression in prostate cancer
  • Epigenetic deregulation in castration resistant prostate cancer
  • Molecular Biomarkers for indolent prostate cancer

Mitrofanova, A.*, Aytes, A.*, Shen, M.M., Abate-Shen, C. & Califano, A. (2015). A
systems biology approach to predict drug response for human prostate cancer based on in vivo
preclinical analyses of mouse models. Cell Rep. Sep 29;12(12):2060-71. *Equal contribution

 

Jonathan F. Goodwin, Vishal Kothari, Justin M. Drake, Shuang Zhao, Emanuela Dylgjeri,
Jeffry L. Dean, Matthew J. Schiewer, Christopher McNair, Jennifer K. Jones, Alvaro Aytes,
Michael S. Magee, Adam E. Snook, Ziqi Zhu, Robert B. Den, Ruth C. Birbe, Leonard G.
Gomella, Nicholas A. Graham, Ajay A. Vashisht, James A. Wohlschlege, Thomas G. Graeber,
R. Jeffrey Karnes, Mandeep Takhar, Elai Davicioni, Scott A. Tomlins, Cory Abate-Shen, Nima
Sharifi, Owen N. Witte, Felix Y. Feng, and Karen E. Knudsen. (2015) DNA-PK mediated
transcriptional regulation drives tumor progression and metastasis. Cancer Cell Jul
13;28(1):97-113

 

Aytes, A., Mitrofanova, A, Lefebvre, C, Alvarez, MJ, Castillo-Martin, M., Zheng, T.,
Eastham, JA, Gopalan, A., Pienta, K.J., Shen, M.M., Califano, A., & Abate-Shen, C. (2014)
Cross-species analysis of genome-wide regulatory networks identifies a synergistic interaction
between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5); 638-
651

 

Aytes, A., Mitrofanova, A., Kinkade, C.W., Lefebvre, C., Lei, M., Phelan, V., Lekaye, H.C.,
Koutcher, J.A., Cardiff, R.D., Califano, A., Shen, M.M., & Abate-Shen, C. (2013) ETV4
promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse
model
of advanced prostate cancer. Proc Natl Acad Sci U S A 110(37):E3506-3515.

 

Irshad, S., Bansal, M., Castillo-Martin, M., Zheng, T., Aytes, A., Wenske, S., Le Magnen,
C., Guarnieri, P., Sumazin, P., Benson, M.C., Shen, M.M., Califano, A., & Abate-Shen, C.
(2013) A molecular signature predictive of indolent prostate cancer. Science Translational
Medicine 5(202):202ra122.

Agency: BBVA Foundation
Title: Epigenetic mechanisms in castration resistant prostate cancer: Therapeutic opportunities
for drug combinations of androgen receptor antagonists and epigenetic drugs
IP: Alvaro Aytes
Period: 18 months (2017-2018)
Amount: 40.000 €

 

Agency: European Association of Urology Research foundation
Title: Investigating causal mechanisms and novel therapeutic targets in CRPC after AR
blockade failure
IP: Alvaro Aytes
Period: 01/2016 - 12/2019
Number of Participants: 6
Amount: 240.000 €

 

Agency: ISCIII
Title: Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and
CENPF in the deregulation of the epigenetic control of gene expression.
IP: Alvaro Aytes
Period: 02/2016 - 01/2019
Amount: 121.500 €

 

Agency: MINECO - Programa Retos, Jovenes Investigadores
Title: A systems approach to identify molecular drivers and new therapeutic targets in
metastatic prostate cancer
IP: Alvaro Aytes
Period: 2015-2018
Amount: 170.000 €
Declined due to incompatibility with the Miguel Servet Grant

 

Agency: National Center for Advancing Translational Sciences - NIH
Title: A systems approach to identify molecular drivers and new therapeutic targets in
metastatic prostate cancer
IP: Alvaro Aytes
Period: 07/2013 - 06/2014
Amount: $ 50.000

 

Agency: European Community -FP7
Title: Assembly of a prostate cancer genome-wide molecular interactome for the identification
of the key regulatory genes of malignant transformation and new targets for therapeutic
intervention
IP: Alvaro Aytes
Period: 08/2010 - 07/2013

imatge personal
 

Group leader

Alvaro Aytes
Telephone  
+34 932607464
E-mail  
aaytes@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell